Jose Amigo-Seijas

Santiago De Compostela, GA, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders.

GLP-1 receptor agonists in addiction and affective disorders: Implications for dual disorders.

Journal: Progress in neuro-psychopharmacology & biological psychiatry

Published: May 23, 2026

Corrigendum to "Real-World Impact of GLP-1 Receptor Agonists on Health-Related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)" [Clin Ther. 2026;48:291-293].

Corrigendum to "Real-World Impact of GLP-1 Receptor Agonists on Health-Related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study)" [Clin Ther. 2026;48:291-293].

Journal: Clinical therapeutics

Published: May 23, 2026

Cardiovascular health as an unmet priority in addiction medicine: Implications of recent cardiovascular strategies.

Cardiovascular health as an unmet priority in addiction medicine: Implications of recent cardiovascular strategies.

Journal: Addiction (Abingdon, England)

Published: January 15, 2026

Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.

Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.

Journal: European heart journal open

Published: December 17, 2025

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.

Journal: International journal of clinical pharmacy

Published: November 14, 2025

Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).

Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).

Journal: Clinical therapeutics

Published: November 08, 2025

Prospective study of continuous rhythm monitoring in patients with early post-infarction systolic dysfunction: clinical impact of arrhythmias detected by an implantable cardiac monitoring device with real-time transmission-the TeVeO study protocol.

Prospective study of continuous rhythm monitoring in patients with early post-infarction systolic dysfunction: clinical impact of arrhythmias detected by an implantable cardiac monitoring device with real-time transmission-the TeVeO study protocol.

Journal: BMJ open

Published: May 02, 2025

Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.

Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.

Journal: Diabetes & metabolic syndrome

Published: November 19, 2024

Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.

Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.

Journal: Diseases (Basel, Switzerland)

Published: August 12, 2024

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure.

Journal: European journal of clinical investigation

Published: August 06, 2024

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study.

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: August 02, 2023

Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.

Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.

Journal: The American journal of cardiology

Published: June 12, 2023

Showing 1-12 of 23

Last Updated: 09/26/2026